<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592200</url>
  </required_header>
  <id_info>
    <org_study_id>CSUB0092</org_study_id>
    <nct_id>NCT02592200</nct_id>
  </id_info>
  <brief_title>Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women</brief_title>
  <official_title>A Double Blind Placebo-Controlled Study on the Effect of the Probiotic Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women - Proof of Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGaia AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the change in frequency of complete spontaneous bowel
      movements (CSBMs) after 4 weeks of oral supplementation with Lactobacillus gasseri DSM 27123
      in healthy adult women with functional constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of complete spontaneous bowel movements (CSBMs)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Stool Consistency (Bristol Stool Form scale)</measure>
    <time_frame>Baseline, week 1, 2, 3 and 4</time_frame>
    <description>Change in Bristol Stool Form Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Assessment of Constipation Symptoms (PAC-SYM)</measure>
    <time_frame>Baseline, week 1, 2, 3 and 4 (change from baseline)</time_frame>
    <description>Change in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Baseline, week 1, 2, 3 and 4</time_frame>
    <description>Change in Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatement related adverse events</measure>
    <time_frame>During the whole study - 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Lactobacillus gasseri DSM 27123 in faeces</measure>
    <time_frame>4 weeks</time_frame>
    <description>qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for laxative medication</measure>
    <time_frame>During the treatment period - 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>Lactobacillus gasseri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules (two doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus gasseri DSM 27123</intervention_name>
    <description>109 CFU (divided in two doses) per day for 28 days</description>
    <arm_group_label>Lactobacillus gasseri</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two doses per day for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subjects have to meet all of the following criteria to be eligible to enter the study:

          1. Willing and able to provide informed consent

          2. Women aged 18-49 years at Visit 1

          3. BMI ≥18 and ≤29 at Visit 1

          4. Suffering of functional constipation as defined by the Rome III criteria for
             functional constipation

          5. Comply with the requirement not to use any other probiotic products from Visit 1 and
             throughout the study period

          6. Not pregnant or breastfeeding

          7. Using adequate contraceptive measures

          8. Ability to understand and comply with the requirements of the study, as judged by the
             Investigator

        Exclusion Criteria:

          1. Hypersensitivity or allergy to the investigational product, to chemically related
             products or to comparator/placebo

          2. Well-known, organic cause of constipation

          3. Anorectal pathology

          4. Previous gastrointestinal surgery

          5. Any alarming symptoms (i.e. rectal bleeding, weight loss, jaundice) as judged by the
             Investigator

          6. Spinal anomalies and injuries

          7. Use of antibiotics within 4 weeks prior to Visit 1

          8. Use of products containing probiotics more than once a week in the previous 3 weeks

          9. Mental or behavioural disorders as judged by the Investigator

         10. Food allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Hellström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTC, Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Constipation</keyword>
  <keyword>Lactobacillus gasseri DSM 27123</keyword>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

